Challenges Seen With Novel Agents in Multiple Myeloma
Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.
Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.
At the start of her practice, lenalidomide (Revlimid) and bortezomib (Velcade) were the only 2 novel agents available for patients with myeloma. Now, there are monoclonal antibodies, checkpoint inhibitors, CAR T cells, and many more.
With so many novel and targeted agents appearing in the treatment landscape, it is hard to keep up with all of the latest data for these drugs. In most cases, there is still not enough information available on the overall survival or progression-free survival with these drugs, Madduri says.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
